Tadalafil Tablet, Film Coated
Product Images NDC 82804-112

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 82804-112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 01)

Chemical structure of tadalafil, showing its molecular framework with fused rings and functional groups distinctive to the compound.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 02)

Four line graphs showing the difference in blood pressure measurements (Tadalafil minus placebo) over time in hours. The graphs depict standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure, with time points up to 96 hours on the x-axis and the difference in mmHg on the y-axis.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 03)

A set of two line graphs displaying changes in systolic blood pressure over 24 hours post-dose. The top graph shows standing systolic blood pressure changes comparing tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg. The bottom graph displays supine systolic blood pressure changes for the same comparisons. Time post-dose (hours) is on the x-axis and blood pressure change (mmHg) on the y-axis.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 04)

A line graph showing changes in systolic blood pressure (mmHg) over time after administration of tadalafil 20 mg or placebo, with or without 8 mg once-daily doxazosin. The x-axis represents time in hours post-dose up to 12 hours, and the y-axis shows systolic blood pressure change from baseline.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 05)

A pharmacokinetic curve showing plasma tadalafil concentration (µg/L) over time (hours) for three conditions: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 consecutive days. The graph includes error bars indicating variability at each time point.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 06)

A line graph showing the change from baseline in IPSS total score over 12 weeks of treatment. It compares tadalafil 5 mg and placebo, with data points at 0, 4, 8, and 12 weeks. The graph shows a greater decrease in IPSS total score for tadalafil 5 mg compared to placebo, with statistical significance indicated at p<0.01.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 07)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment for tadalafil 5 mg versus placebo. The x-axis shows duration of treatment in weeks, while the y-axis shows change from baseline. Tadalafil shows greater reductions than placebo, with statistically significant differences indicated.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 08)

A line graph comparing least-squares mean change from baseline over 26 weeks of therapy between Tadalafil/Finasteride and Placebo/Finasteride treatments. The graph shows greater reduction in measurements for Tadalafil/Finasteride at weeks 4, 12, and 26, with statistical annotations indicating significance at certain points.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 09)

A line graph depicting change from baseline in IPSS total scores over 12 weeks of treatment. The graph compares tadalafil 5 mg (solid line with circles) and placebo (dashed line with triangles), showing a decreasing trend in scores over time for both groups, with tadalafil showing a greater reduction. Significance is indicated at p < 0.01.*

FDA Label Image

Unichem Logo (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 10)

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 11)

FDA Label Image

82804-112-90 (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 17)

Label for tadalafil 20 mg film-coated tablets, package of 90, manufactured by Unichem Laboratories Ltd and labeled by Proficient Rx LP. Tablets are yellow, almond-shaped, with '289' debossed on one side and 'U' on the other. The label includes storage instructions and warnings not to split tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.